Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan in Symptomatic Non-Erosive Gastroesophageal Reflux Disease
NCT07752407Phase 3Recruiting
- Sponsor
- Phathom Pharmaceuticals
- Start
- Sep 2026
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
A Phase 3 trial of vonoprazan in Non-erosive Gastroesophageal Reflux Disease (NERD), sponsored by Phathom Pharmaceuticals. Started Sep 2026; status: recruiting.
02
Drugs
vonoprazan
03
Conditions
Non-erosive Gastroesophageal Reflux Disease (NERD)
Beyond the preview
Go deeper on NCT07752407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07752407.